Meda Pharms Drug Patent Portfolio
Meda Pharms owns 2 orange book drugs protected by 4 US patents Given below is the list of Meda Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof | 04 Jun, 2028 | Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof | 22 Nov, 2025 | Active |
| US6024981 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6221392 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
Latest Legal Activities on Meda Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Meda Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 May, 2023 | US8071073 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Sep, 2021 | US9919050 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Feb, 2021 | US8518919 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 May, 2019 | US8071073 (Litigated) |
| Post Issue Communication - Certificate of Correction | 23 May, 2018 | US9919050 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Mar, 2018 | US9919050 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Mar, 2018 | US9919050 |
|
Email Notification
Critical
| 01 Mar, 2018 | US9919050 |
|
Issue Notification Mailed
Critical
| 28 Feb, 2018 | US9919050 |
| Dispatch to FDC | 07 Feb, 2018 | US9919050 |
|
Application Is Considered Ready for Issue
Critical
| 02 Feb, 2018 | US9919050 |
|
Issue Fee Payment Received
Critical
| 01 Feb, 2018 | US9919050 |
|
Issue Fee Payment Verified
Critical
| 01 Feb, 2018 | US9919050 |
| Mail Post Card | 10 Nov, 2017 | US9919050 |
|
Mail Notice of Allowance
Critical
| 02 Nov, 2017 | US9919050 |
Meda Pharms's Drug Patent Litigations
Meda Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2014, against patent number US8071073. The petitioner Impax Laboratories, Inc., challenged the validity of this patent, with Meda Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Meda Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8071073 | May, 2014 |
Terminated-Denied
(29 Jul, 2014)
| Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
Meda Pharms's Family Patents
Meda Pharms Drug List
Given below is the complete list of Meda Pharms's drugs and the patents protecting them.
1. Astepro
Astepro is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(3 years from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(1 year, 1 month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astepro's drug page
2. Reglan Odt
Reglan Odt is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reglan Odt's drug page